FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Response of Sport Horses to Different Formulations of Equine...
Vaccines2020; 8(3); doi: 10.3390/vaccines8030372

Response of Sport Horses to Different Formulations of Equine Influenza Vaccine.

Abstract: The international governing body of equestrian sports requires that horses be vaccinated against equine influenza within 6 months and 21 days of competing. The aim of this study was to compare the antibody response of young sport horses to six-monthly booster vaccination with equine influenza vaccines of different formulations. An inactivated vaccine was allocated to 35 horses and subunit and recombinant vaccines were allocated to 34 horses each. After vaccination, all horses were monitored for evidence of adverse reactions. Whole blood samples were collected at the time of vaccination and on nine occasions up to six months and 21 days post vaccination. Antibodies against equine influenza were measured by single radial haemolysis. Transient fever and injection site reactions were observed in several horses vaccinated with each vaccine. Only two horses failed to seroconvert post booster vaccination but there was a delayed response to the recombinant vaccine. The antibody response to the recombinant vaccine was lower than that induced by the whole-inactivated and subunit vaccines up to three months post vaccination. Thereafter, there was no significant difference. By six months post vaccination, the majority of horses in all three groups were clinically but not virologically protected. There was minimal decline in antibody titres within the 21-day grace period.
Get Full Text
Publication Date: 2020-07-10 PubMed ID: 32664411PubMed Central: PMC7563521DOI: 10.3390/vaccines8030372Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates the effects of different types of equine influenza vaccines on young sport horses. The study is aimed at comparing how effective these vaccines are in eliciting an immune response, and whether reactions occur post-vaccination, ultimately to comply with international governing body regulations.

Research Methodology

  • The study was set to compare the antibody response of young sport horses to different forms of equine influenza vaccines, given on a six-monthly booster vaccination schedule following the regulations of the international governing body of equestrian sports.
  • In the experiment, 35 horses were allocated an inactivated vaccine while 34 horses were each given subunit and recombinant vaccines.
  • Post-vaccination, all horses were monitored for possible adverse reactions such as fever and reactions at the injection site.
  • Simultaneously, whole blood samples were collected from each horse at different intervals ranging from the time of vaccination to six months and 21 days post-vaccination.

Observations and Results

  • The antibody response against equine influenza in horses was measured using a technique called single radial haemolysis.
  • In several horses vaccinated with each type of vaccine, temporary fever and reactions at the injection site were observed.
  • Only two horses failed to seroconvert – or produce detectable antibodies in the blood – following the booster vaccination.
  • There was a delay in seroconversion in horses that received the recombinant vaccine, and the initial antibody response to this vaccine was lower than that induced by the inactivated and subunit vaccines.
  • However, this difference in antibody response was not significant past three months post-vaccination. By the six months post-vaccination interval, there was no notable difference in the antibody response between the three groups of horses.
  • Although clinically protected, the majority of horses were not virologically protected six months after vaccination, meaning while they showed no signs of disease, the virus could still be present.
  • There was a minimal reduction in antibody titres – or concentrations – within the 21-day grace period.

Conclusions

  • The results demonstrated that the types of equine influenza vaccine formulations could impact the response time and degree of seroconversion in sport horses.
  • While all vaccines induced the desired immune response, there were variations in the timelines and the intensity of these responses.
  • The recombinant vaccine was found to show delayed and initially lower responses compared to the inactivated and subunit vaccines.
  • The majority of the horses were clinically but not virologically protected by six months, underpinning the need for regular six-month booster vaccinations in sport horses.

Cite This Article

APA
Entenfellner J, Gahan J, Garvey M, Walsh C, Venner M, Cullinane A. (2020). Response of Sport Horses to Different Formulations of Equine Influenza Vaccine. Vaccines (Basel), 8(3). https://doi.org/10.3390/vaccines8030372

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 8
Issue: 3

Researcher Affiliations

Entenfellner, Johanna
  • School of Veterinary Medicine, Bischofsholer Damm 15, 30173 Hannover, Germany.
Gahan, Jacinta
  • Irish Equine Centre, Johnstown, Naas, Co. Kildare, W91 RH93 Johnstown, Ireland.
Garvey, Marie
  • Irish Equine Centre, Johnstown, Naas, Co. Kildare, W91 RH93 Johnstown, Ireland.
Walsh, Cathal
  • Department of Mathematics and Statistics, University of Limerick, V94 T9PX Limerick, Ireland.
Venner, Monica
  • Pferdeklinik Destedt GmbH, Destedt, Trift 4, 38162 Cremlingen, Germany.
Cullinane, Ann
  • Irish Equine Centre, Johnstown, Naas, Co. Kildare, W91 RH93 Johnstown, Ireland.

Grant Funding

  • DAFM_IEC_OIE / Department of Agriculture, Food and the Marine, Ireland

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 33 references
  1. Cullinane A, Newton JR. Equine influenza—A global perspective.. Vet. Microbiol. 2013;167:205–214.
    doi: 10.1016/j.vetmic.2013.03.029pubmed: 23680107google scholar: lookup
  2. Paillot R. A systematic review of recent advances in equine influenza vaccination.. Vaccines 2014;2:797.
    doi: 10.3390/vaccines2040797pmc: PMC4494246pubmed: 26344892google scholar: lookup
  3. Gildea S, Garvey M, Lyons P, Lyons R, Gahan J, Walsh C, Cullinane A. Multifocal equine influenza outbreak with vaccination breakdown in thoroughbred racehorses.. Pathogens 2018;7:43.
    doi: 10.3390/pathogens7020043pmc: PMC6027538pubmed: 29673169google scholar: lookup
  4. Gildea S, Lyons P, Lyons R, Gahan J, Garvey M, Cullinane A. Annual booster vaccination and the risk of equine influenza to Thoroughbred racehorses.. Equine Vet. J. 2020;52:509–515.
    doi: 10.1111/evj.13210pubmed: 31750956google scholar: lookup
  5. Mumford JA, Wood J. Establishing an acceptability threshold for equine influenza vaccines.. Dev. Biol. Stand. 1992;79:137–146.
    pubmed: 1286748
  6. Mumford J, Jessett D, Rollinson E, Hannant D, Draper M. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines.. Vet. Rec. 1994;134:158–162.
    doi: 10.1136/vr.134.7.158pubmed: 8160328google scholar: lookup
  7. Mumford JA, Jessett D, Dunleavy U, Wood J, Hannant D, Sundquist B, Cook RF. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines.. Vaccine 1994;12:857–863.
    doi: 10.1016/0264-410X(94)90297-6pubmed: 7975864google scholar: lookup
  8. Newton JR, Verheyen K, Wood JL, Yates PJ, Mumford JA. Equine influenza in the United Kingdom in 1998.. Vet. Rec. 1999;145:449–452.
    doi: 10.1136/vr.145.16.449pubmed: 10576277google scholar: lookup
  9. Newton JR, Townsend HG, Wood JL, Sinclair R, Hannant D, Mumford JA. Immunity to equine influenza: Relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet. J. 2000;32:65–74.
    doi: 10.2746/042516400777612116pubmed: 10661388google scholar: lookup
  10. Mumford JA. Collaborative study for the establishment of three European Pharmacopoeia Biological Reference Preparations for equine influenza horse antiserum.. Pharmeuropa 2000;1:7–21.
  11. Daly J, Daas A, Behr-Gross ME. Collaborative study for the establishment of a candidate equine influenza subtype 2 American-like strain A/EQ/South Africa/4/03-horse antiserum biological reference preparation.. Pharmeuropa Bio/Biol. Stand. Programme EDQM 2007;2007:7–14.
    pubmed: 18413133
  12. Mumford JA. Epidemiology and vaccinology of equine influenza, quality control of equine influenza vaccines; Proceedings of the International Symposium Organised by the European Directorate for the Quality of Medicines (EDQM), Council of Europe; Budapest, Hungary. 10–11 December 2001. Strasbourg, France: EDQM 2001. pp. 7–12.
  13. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings—A randomised blind study.. Vaccine 2011;29:9214–9223.
    doi: 10.1016/j.vaccine.2011.09.101pubmed: 21983355google scholar: lookup
  14. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt horses—A randomised blind study.. Vaccine 2011;29:3917–3922.
    doi: 10.1016/j.vaccine.2011.03.003pubmed: 21419776google scholar: lookup
  15. Gildea S, Arkins S, Cullinane A. A comparative antibody study of the potential susceptibility of Thoroughbred and non-Thoroughbred horse populations in Ireland to equine influenza virus.. Influenza Other Respir. Viruses 2010;4:363–372.
    doi: 10.1111/j.1750-2659.2010.00163.xpmc: PMC4634612pubmed: 20958930google scholar: lookup
  16. Gildea S, Quinlivan M, Arkins S, Cullinane A. The molecular epidemiology of equine influenza in Ireland from 2007–2010 and its international significance.. Equine Vet. J. 2012;44:387–392.
    doi: 10.1111/j.2042-3306.2011.00472.xpubmed: 21978127google scholar: lookup
  17. R CoreTeam. R: A Language and Environment for Statistical Computing.. R Foundation for Statistical Computing; Vienna, Austria: 2016.
  18. Heldens JGM, Weststrate MW, van den Hoven R. Area under the curve calculations as a tool to compare the efficacy of equine influenza vaccines—A retrospective analysis of three independent field trials.. J. Immunol. Methods 2002;264:11–17.
    doi: 10.1016/S0022-1759(01)00571-3pubmed: 12191504google scholar: lookup
  19. Cullinane A, Gahan J, Walsh C, Nemoto M, Entenfellner J, Olguin-Perglione C, Garvey M, Huang Fu TQ, Venner M, Yamanaka T. Evaluation of current equine influenza vaccination protocols prior to shipment, guided by OIE standards.. Vaccines 2020;8:107.
    doi: 10.3390/vaccines8010107pmc: PMC7157717pubmed: 32121419google scholar: lookup
  20. Daly JM, Yates PJ, Newton JR, Park A, Henley W, Wood JLN, Davis-Poynter N, Mumford JA. Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines.. Vaccine 2004;22:4101–4109.
    doi: 10.1016/j.vaccine.2004.02.048pubmed: 15364463google scholar: lookup
  21. de la Rua-Domenech R, Reid SW, Gonzalez-Zariquiey AE, Wood JL, Gettinby G. Modelling the spread of a viral infection in equine populations managed in Thoroughbred racehorse training yards.. Prev. Vet. Med. 1999;47:61–77.
    doi: 10.1016/S0167-5877(00)00161-6pubmed: 11018735google scholar: lookup
  22. Park AW, Wood JL, Newton JR, Daly J, Mumford JA, Grenfell BT. Optimising vaccination strategies in equine influenza.. Vaccine 2003;21:2862–2870.
    doi: 10.1016/S0264-410X(03)00156-7pubmed: 12798628google scholar: lookup
  23. Newton JR, Park AW, Wood JLN. Maximizing the benefits of vaccination against equine influenza.. Equine Respiratory Diseases International Veterinary Information Service; Ithaca, NY, USA: 2004.
  24. Andersen SA, Petersen HH, Ersbøll AK, Falk-Rønne J, Jacobsen S. Vaccination elicits a prominent acute phase response in horses.. Vet. J. 2012;191:199–202.
    doi: 10.1016/j.tvjl.2011.01.019pubmed: 21371917google scholar: lookup
  25. Gershwin LJ, Netherwood KA, Norris MS, Behrens NE, Shao MX. Equine IgE responses to non-viral vaccine components.. Vaccine 2012;30:7615–7620.
    doi: 10.1016/j.vaccine.2012.10.029pubmed: 23088888google scholar: lookup
  26. Gärtner BC, Meyer T. Vaccination in elite athletes.. Sports Med. 2014;44:1361–1376.
    doi: 10.1007/s40279-014-0217-3pmc: PMC4171584pubmed: 24986118google scholar: lookup
  27. Minke JM, Toulemonde CE, Coupier H, Guigal PM, Dinic S, Sindle T, Jessett D, Black L, Bublot M, Pardo MC. Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge.. Am. J. Vet. Res. 2007;68:213–219.
    doi: 10.2460/ajvr.68.2.213pubmed: 17269889google scholar: lookup
  28. Crouch CF, Daly J, Hannant D, Wilkins J, Francis MJ. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an ‘American lineage’ H3N8 virus.. Vaccine 2004;23:418–425.
    doi: 10.1016/j.vaccine.2004.01.074pubmed: 15530689google scholar: lookup
  29. Bryant NA, Paillot R, Rash AS, Medcalf E, Montesso F, Ross J, Watson J, Jeggo M, Lewis NS, Newton JR. Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak.. Vet. Res. 2010;41:19.
    doi: 10.1051/vetres/2009067pmc: PMC2790087pubmed: 19863903google scholar: lookup
  30. Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.. Vet. Immunol. Immunopathol. 2006;112:225–233.
    doi: 10.1016/j.vetimm.2006.02.007pubmed: 16621023google scholar: lookup
  31. Paillot R, Grimmett H, Elton D, Daly JM. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.. Vet. Res. 2008;39:21.
    doi: 10.1051/vetres:2007062pubmed: 18252187google scholar: lookup
  32. Paillot R, Prowse L, Montesso F, Huang CM, Barnes H, Escala J. Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.. Vet. Microbiol. 2013;162:396–407.
    doi: 10.1016/j.vetmic.2012.10.019pubmed: 23146168google scholar: lookup
  33. . OIE Expert surveillance panel on equine influenza vaccine composition—Conclusions and recommendations.. Off. Int. Epizoot. Bull. 2010;2:44–45.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.